Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease

Autoimmunity Reviews

Volumn 10, Issue 3, 2011, Pages 155-162

  Zold, Eva ^a   Szodoray, Peter ^b   Nakken, Britt ^b   Barath, Sandor ^a   Kappelmayer, Janos ^a   Csathy, Laszlo ^a   Hajas, Agota ^a   Sipka, Sandor ^a   Gyimesi, Edit ^a   Gaal, Janos ^c   Barta, Zsolt ^a   Hallay, Judit ^a   Szegedi, Gyula ^a   Bodolay, Edit ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF OSLO   (Norway)

^c Kenezy Korhaz Rendelointezet   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4;

ADULT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DRUG DOSE COMPARISON; FEMALE; HUMAN; IMMUNOREGULATION; OPTIMAL DRUG DOSE; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE; VITAMIN D DEFICIENCY;

BONE DENSITY CONSERVATION AGENTS; CHILD, PRESCHOOL; CONNECTIVE TISSUE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; IMMUNE SYSTEM DISEASES; INFANT; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; T-LYMPHOCYTES, HELPER-INDUCER; TIME FACTORS; VITAMIN D DEFICIENCY;

EID: 78751633052     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.09.018     Document Type: Review

References (68)

1. Deluca H.F., Cantorna M.T. Vitamin D: its role and uses in immunology. FASEB J 2001, 15:2579-2585.
2. Adorini L., Penna G. Control of autoimmun diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4:404-412.
3. Van Etten E., Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005, 97:93-101.
4. Arnson Y., Amital H., Shoenfeld Y. Vitamin D and autoimmunity: new etiological and therapeutic considerations. Ann Rheum Dis 2007, 66:1137-1142.
5. Souberbielle J.C., Body J.J., Lappe J.M., Plebani M., Shoenfeld Y., Wang T.J., et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010, 11:709-715.
6. Pelajo C.F., Lopez-Benitez J.M., Miller L.C. Vitamin D and autoimmune rheumatologic disorders. Autoimmun Rev 2010, 7:507-510. Epub.
7. Albert P.J., Proal A.D., Marshall T.G. Vitamin D: the alternative hypothesis. Autoimmun Rev 2009, 8:639-644.
8. Cutolo M., Otsa K. Review: vitamin D, immunity and lupus. Lupus 2008, 17:6-10.
9. Szodoray P., Nakken B., Gaal J., Jomsson R., Szegedi A., Zold E., et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol 2008, 68:261-269.
10. Adorini L. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 2004, 16:127-134.
11. Steinman L. A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-145.
12. Griffin M.D., Lutz W.H., Phan V.A., Bachman L.A., McKean D.J., Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 2000, 270:701-708.
13. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
14. Ruiz-Irastorza G., Egurbide M.V., Olivares N., Martinez-Berriotxoa A., Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology 2008, 47:920-923.
15. Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004, 50:72-77.
16. Cutolo M., Otsa K., Uprus M., Paolino S., Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmun Rev 2007, 1:59-64.
17. Smolders J., Peelen E., Thewissen M., Menheere P., Teryaert J.W., Hupperts R., et al. The revelance of vitamin D receptor gene polymorphisms for vitamin D research in muliple sclerosis. Autoimmun Rev 2009, 7:621-626.
18. Selmi C., Tsuneyama K. Nutrition, geoepidemiology, and autoimmunity. Autoimmun Rev 2010, 5:A267-A270.
19. Bodolay E., Csiki Z., Ben T., Szekanecz Z., Kiss E., Zeher M., et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003, 21:313-320.
20. Zold E., Szodoray P., Gaal J., Kappelmayer J., Csathy L., Gyimesi E., et al. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 2008, 10:R123.
21. Mosca M., Tani C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol 2007, 21:1011-1023.
22. Zold E., Szodoray P., Kappelmayer J., Gaal J., Csathy L., Barath S., et al. Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scan J Rheumatol 2010, doi:10.3109/03009741003781951.
23. Andjelkovic Z., Vojinovic J., Pejnovic N., Popovic M., Dujic A., Mitrovic D., et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999, 17:453-456.
24. Bodolay E., Aleksza M., Antal-Szalmás P., Végh J., Szodoray P., Soltész P., et al. Serum cytokine levels, type 1 and intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 2002, 29:2136-2142.
25. Adams J.S., Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008, 4:80-90.
26. Doria A., Arienti S., Rampudda M., Canova M., Tonon M., Sarzi-Puttini P. Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 2008, 3:192-197.
27. Borba V.Z., Vieira J.G., Kasamatsu T., Radominski S.C., Sato E.I., Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporosis Int 2009, 20:27-33.
28. Kamen D.L., Cooper G.S., Bouali H., Shaftman S.R., Hollis B.W., Gilkeson G.S. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006, 5:114-117.
29. Alele J.D., Kamen D.L. The importance of inflammation and vitamin D status in SLE-associated osteoporosis. Autoimmun Rev 2010, 3:137-139.
30. Munger K.L., Zhang S.M., O'Reilly E., Hernán M.A., Olek M.J., Willett W.C., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
31. Ringe J.D., Schacht E. Improving the ourcome of establshed therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int 2007, 28:103-111.
32. Moe S., Wazny L.D., Martin J.E. Oral calcitriol versus oral alfacalcidol for the teratment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Can J Clin Pharmacol 2008, 15:36-43.
33. Dukas L., Bischoff H.A., Lindpaintner L.S., Schacht E., Birkner-Binder D., Damm T.N., et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500mg daily. JAGS 2004, 52:230-236.
34. Romagnani S. Human Th17 cells. Arthritis Res Ther 2008, 10:206-218.
35. Gambinery E., Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003, 15:430-435.
36. Khattri R., Cox T., Ysayko S.A., Rasdell F. Az essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4:337-342.
37. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
38. Ait-Outfella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
39. Kukreja A., Cost G., Marker J., Zhang C., Sun Z., Lin-Su K., et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002, 109:131-140.
40. Mottonen M., Heikkinen J., Mustonen L., Isomaki P., Luukkainen R., Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol 2005, 140:360-367.
41. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005, 174:164-173.
42. Balandina A., Lecart S., Dartevelle P., Saoudi A., Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005, 105:735-741.
43. Baráth S., Sipka S., Szodoray P., Szegedi A., Aleksza M., Vegh J., et al. Regulatory T cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 2006, 35:300-304.
44. Lyssuk E.Y., Torgashina A.V., Soloviev S.K., Nassonov E.L., Bykovskaia S.N. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007, 601:113-119.
45. Mellor-Pita S., Citores M.J., Castejon R., Tutor-Ureta P., Yebra-Bango M., Andreu J.L., et al. Decrease of regulatory T cells in patients with systemic lupus erythematosus. Ann Rheum Dis 2006, 65:553-554.
46. Alvarado-Sanchez B., Hernandez-Castro B., Portales-Perez D., Baranda L., Layseca-Espinosa E., Abud-Mendoza C., et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006, 27:110-118.
47. Valencia X., Yarboro C., Illei G., Lipsky P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007, 178:2579-2588.
48. Bettelli E., Korn T., Oukka M., Kuchroo V.K. Induction and effector functions of T(H)17 cells. Nature 2008, 453:1051-1057.
49. Aggarval S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by a production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
50. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
51. Wong C.K., Lit L.C.W., Tam L.S., Li E.K.M., Wong P.T.Y., Lam C.W.K. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-imunity. Clin Immunol 2008, 127:385-393.
52. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
53. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007, 148:32-46.
54. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463.
55. Nalbandian A., Crispin J.C., Tsokos G.C. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009, 157:209-215.
56. Shah K., Lee W.W., Lee S.H., Kim S.H., Kang S.W., Craft J., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R53.
57. Kwan B.C., Tam L.S., Lai K.B., Lai F.M., Li E.K., Wang G., et al. The gene expression of type 17T-helper cell-related cytokines in urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxf) 2009, 48:1491-1497.
58. Penna G., Amuchastegui S., Cossetti C., Aquilano F., Mariani R., Sanvito F., et al. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006, 177:8504-8511.
59. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
60. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum 2007, 56:2936-2946.
61. Chen Z., O'Shea J.J. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008, 41:87-102.
62. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007, 8:950-957.
63. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006, 116:1317-1326.
64. Chi W., Zhu X., Yang P., Liu X., Lin X., Zhou H., et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci 2008, 49:3058-3064.
65. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells. Ann NY Acad Sci 2010, 1183:211-221.
66. Kebir H., Ifergan I., Alvarez J.I., Bernard M., Poirier J., Arbour N., et al. Preferential recruitment of interferon-γ-expressing T H 17 cells in multiple sclerosis. Ann Neurol 2009, 66:390-402.
67. McGeachy M.J., Bak-Jensen K.S., Chen Y., Tato C.M., Blumenschein W., Mc Clanahan T., et al. TGF-γ and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007, 8:1390-1397.
68. Alvarado-Sánchez B., Hernández-Castro B., Portales-Pérez D., Baranda L., Layseca-Espinosa E., Abud-Mendoza C., et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006, 27:110-118.